Blog

Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement

Jul 28 • 11 min read

Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL | NASDAQ: IXHL), is pleased to provide its quarterly activities report and appendix 4C for the period ended 30 June 2022. Incannex is undertaking a multitude of U.S. Food and Drug Administration programs for cannabinoid pharmaceutical products and psychedelic medicine therapies administered by health professionals. Cannabinoid IHL-42X:…

Hemplucid Becomes First Startup to Provide Psychedelic Therapy as Employee Healthcare Benefit

Jul 28 • 3 min read

HempLucid, a leading provider of plant-based wellness supplements, is the first startup to offer medically supervised Ketamine-Assisted Therapy (KAP) as an employee benefit. Ketamine is a general anesthetic, first used on the battlefields of Vietnam because it did not slow the heartrate like other anesthetics. Today, ketamine is used by first responders to calm people trying to…

Is This the End Of the Psychedelic PR Crisis?

Jul 28 • 6 min read

For 50 years, psychedelic researchers have been battling a public relations crisis of epic proportions, but the tides are changing! Whether you are a veteran advocate, or just showed up to the party, you should be breaking out the champagne to celebrate the start of a new age for psychedelic medicines. The media has been…

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Jul 28 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United States Patent and Trademark Office that its patent application no. 17/459,284 will be granted on August 9, 2022 in the United States under patent no….

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Jul 28 • 2 min read

Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548